Net revenues of $19.9 million up 12% over Q1 2021 CNSide™ assay volume up 219% over Q1 2021 and up 70% over Q4 2021 Expanded CNSide customer base with additional oncologists from six leading cancer centers Previews re-focused and rationalized strategy following comprehensive business review
Revenues of $17.8 million were driven by RT-PCR COVID-19 testing Initiated full commercial launch of CNSide™ cerebrospinal fluid assay for diagnosing and managing patients with metastatic cancer involving the central nervous system Received approximately 390,000 COVID-19 samples since June 2020
Revenues of $1.4 million increased 41%, revenue per accession increased 27% Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO , May 13, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading provider of molecular technologies designed to provide physicians with clinically
- Revenues increased 27% compared to the first quarter of 2018 - Billable samples grew 7% year over year, and increased 23% vs. the fourth quarter of 2018 - Commercial gains driven primarily by broadened pathology partnership service - Conference call begins at 4:30 p.m.
Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , May 15, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer
- Billable test volume in first quarter 2017 increases 38% over prior-year period- Revenue of $1.68 million includes impact of conversion to accrual-based revenue recognition- Enters into commercial collaborations with two major oncology treatment centers- Signs agreement to provide liquid biopsy testing in landmark clinical trial with ALCMI- Strengthens balance sheet supporting sales force expansion intended to accelerate growth- Company to host conference call at 4:30 p.m. Eastern time today
Announces Increased Revenues and Strong Year-over-Year Growth in Test Volume Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO , May 12, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the
SAN DIEGO --(BUSINESS WIRE)--Jan. 21, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that COVID-19 RT-PCR testing volume has increased in 2022 with the emergence of the Omicron variant.
SAN DIEGO --(BUSINESS WIRE)--Apr. 17, 2023-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12 months ended December 31, 2022 and provides a business update. “I could not be prouder of my Biocept colleagues
Fourth quarter net revenues of $14.0 million driven by RT-PCR COVID-19 testing volume Full year net revenues of $61.2 million increased 123% over the prior year Positive operating cash flow for 2021 of $3.7 million Cash and cash equivalents at 2021 year-end of $28.9 million CNSide™
